217 related articles for article (PubMed ID: 9374381)
1. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
Patterson AV; Saunders MP; Chinje EC; Talbot DC; Harris AL; Strafford IJ
Br J Cancer; 1997; 76(10):1338-47. PubMed ID: 9374381
[TBL] [Abstract][Full Text] [Related]
2. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
Patterson AV; Barham HM; Chinje EC; Adams GE; Harris AL; Stratford IJ
Br J Cancer; 1995 Nov; 72(5):1144-50. PubMed ID: 7577460
[TBL] [Abstract][Full Text] [Related]
3. NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.
Saunders MP; Patterson AV; Chinje EC; Harris AL; Stratford IJ
Br J Cancer; 2000 Feb; 82(3):651-6. PubMed ID: 10682679
[TBL] [Abstract][Full Text] [Related]
4. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
Keohane A; Godden J; Stratford IJ; Adams GE
Br J Cancer; 1990 May; 61(5):722-6. PubMed ID: 2110815
[TBL] [Abstract][Full Text] [Related]
5. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
Elwell JH; Siim BG; Evans JW; Brown JM
Biochem Pharmacol; 1997 Jul; 54(2):249-57. PubMed ID: 9271329
[TBL] [Abstract][Full Text] [Related]
6. Non-nuclear localized human NOSII enhances the bioactivation and toxicity of tirapazamine (SR4233) in vitro.
Chinje EC; Cowen RL; Feng J; Sharma SP; Wind NS; Harris AL; Stratford IJ
Mol Pharmacol; 2003 Jun; 63(6):1248-55. PubMed ID: 12761334
[TBL] [Abstract][Full Text] [Related]
7. Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines.
Ramji S; Lee C; Inaba T; Patterson AV; Riddick DS
Cancer Res; 2003 Oct; 63(20):6914-9. PubMed ID: 14583491
[TBL] [Abstract][Full Text] [Related]
8. Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
Chinje EC; Patterson AV; Saunders MP; Lockyer SD; Harris AL; Stratford IJ
Br J Cancer; 1999 Dec; 81(7):1127-33. PubMed ID: 10584872
[TBL] [Abstract][Full Text] [Related]
9. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase.
Fitzsimmons SA; Lewis AD; Riley RJ; Workman P
Carcinogenesis; 1994 Aug; 15(8):1503-10. PubMed ID: 8055626
[TBL] [Abstract][Full Text] [Related]
10. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
Riley RJ; Hemingway SA; Graham MA; Workman P
Biochem Pharmacol; 1993 Mar; 45(5):1065-77. PubMed ID: 8461036
[TBL] [Abstract][Full Text] [Related]
11. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
Jounaidi Y; Waxman DJ
Cancer Res; 2000 Jul; 60(14):3761-9. PubMed ID: 10919648
[TBL] [Abstract][Full Text] [Related]
12. The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.
Kim JY; Patterson AV; Stratford IJ; Hendry JH
Anticancer Drugs; 2004 Jan; 15(1):71-7. PubMed ID: 15090746
[TBL] [Abstract][Full Text] [Related]
13. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
Olive PL
Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
[TBL] [Abstract][Full Text] [Related]
14. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver.
Walton MI; Wolf CR; Workman P
Biochem Pharmacol; 1992 Jul; 44(2):251-9. PubMed ID: 1642640
[TBL] [Abstract][Full Text] [Related]
15. Reductive metabolism of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233) and the induction of unscheduled DNA synthesis in rat and human derived cell lines.
Cahill A; White IN
Carcinogenesis; 1990 Aug; 11(8):1407-11. PubMed ID: 2117504
[TBL] [Abstract][Full Text] [Related]
16. The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).
Patterson AV; Robertson N; Houlbrook S; Stephens MA; Adams GE; Harris AL; Stratford IJ; Carmichael J
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):369-72. PubMed ID: 8195035
[TBL] [Abstract][Full Text] [Related]
17. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.
Koch CJ
Cancer Res; 1993 Sep; 53(17):3992-7. PubMed ID: 8358728
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents.
Garner AP; Paine MJ; Rodriguez-Crespo I; Chinje EC; Ortiz De Montellano P; Stratford IJ; Tew DG; Wolf CR
Cancer Res; 1999 Apr; 59(8):1929-34. PubMed ID: 10213502
[TBL] [Abstract][Full Text] [Related]
19. [In vitro oxygen-dependent survival of 2 human cell lines after radiation combined with tirapazamine (SR-4233) and cisplatin].
Lartigau E; Stern S; Guichard M
Cancer Radiother; 2000; 4(3):217-22. PubMed ID: 10897765
[TBL] [Abstract][Full Text] [Related]
20. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure?
Lartigau E; Guichard M
Int J Radiat Biol; 1995 Feb; 67(2):211-6. PubMed ID: 7884290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
